Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: Prognostic value and analysis of their relationships

Clinical and Experimental Immunology

Volumn 150, Issue 1, 2007, Pages 114-123

  El Houda Agueznay, N ^a,b   Badoual, C ^a,b   Hans, S ^b   Gey, A ^b   Vingert, B ^a   Peyrard, S ^c   Quintin Colonna, F ^a   Ravel, P ^d,e   Bruneval, P ^b   Roncelin, S ^b   Lelongt, B ^f   Bertoglio, J ^d   Fridman, W H ^b   Brasnu, D ^b   Tartour, E ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d INSERM   (France)

^e CENTRE DE BIOCHIMIE STRUCTURALE   (France)

^f HÔPITAL TENON   (France)

Author keywords

Cytokine; Head and neck cancer; MMP 9; Prognostic marker; Soluble IL 2 receptor

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE B; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; PHYTOHEMAGGLUTININ;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE;

EID: 34548534894     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03464.x     Document Type: Article

References (63)

1. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003 200:448 64.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002 2:161 74.
3. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005 115:849 60.
4. Shute J. Matrix metalloproteinase-9: marker or mediator of tissue damage in asthma? Clin Exp Allergy 2002 32:168 71.
5. St-Pierre Y, Van Themsche C, Esteve PO. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy 2003 2:206 15.
6. Huang S, Van Arsdall M, Tedjarati S et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002 94:1134 42.
7. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 1994 91:4293 7.
8. Kondraganti S, Mohanam S, Chintala SK et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 2000 60:6851 5.
9. Itoh T, Tanioka M, Matsuda H et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999 17:177 81.
10. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001 17:463 516.
11. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000 103:481 90.
12. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000 2:737 44.
13. Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986 137:3841 4.
14. Semenzato G, Foa R, Agostini C et al. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood 1987 70:396 400.
15. Yano T, Fukuyama Y, Yokoyama H et al. Interleukin-2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer 1996 16:13 19.
16. Ostenstad B. Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer. Acta Oncol 1992 31:413 15.
17. Lein M, Jung K, Laube C et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 2000 85:801 4.
18. Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002 16:791 8.
19. Iizasa T, Fujisawa T, Suzuki M et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999 5:149 53.
20. Vuoristo MS, Laine S, Huhtala H et al. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 2001 37:1629 34.
21. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 2000 83:847 52.
22. Sharma S, Saha K, Shinghal RN, Malik GB. Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour. Cancer Immunol Immunother 1991 33:198 202.
23. Murakami S, Satomi A, Ishida K, Murai H, Okamura Y. Serum soluble interleukin-2 receptor in colorectal cancer. Acta Oncol 1994 33:19 21.
24. Berghella AM, Pellegrini P, Piancatelli D et al. Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother 1994 38:160 6.
25. Huang A, Quinn H, Glover C, Henderson DC, Allen-Mersh TG. The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation. Cancer Immunol Immunother 2002 51:53 7.
26. Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993 53:140 6.
27. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005 11:5158 66.
28. Riedel F, Gotte K, Schwalb J, Hormann K. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Res 2000 20:3045 9.
29. Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H, Werner JA. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res 2002 22:2221 7.
30. Ranuncolo SM, Matos E, Loria D et al. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer 2002 94:1483 91.
31. Gottschlich S, Gorogh T, Lippert BM, Niemann AM, Folz BJ, Werner JA. The soluble interleukin-2 receptor - a marker for squamous cell carcinoma of the upper aerodigestive tract. Anticancer Res 1997 17:2921 2.
32. Tartour E, Deneux L, Mosseri V et al. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study. Cancer 1997 79:1401 8.
33. Tartour E, Mosseri V, Jouffroy T et al. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 2001 357:1263 4.
34. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002 95:1902 10.
35. Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000 17:1099 105.
36. de Vicente JC, Fresno MF, Villalain L, Vega JA, Hernandez Vallejo G. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol 2005 41:283 93.
37. Katayama A, Bandoh N, Kishibe K et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004 10:634 40.
38. Yorioka CW, Coletta RD, Alves F, Nishimoto IN, Kowalski LP, Graner E. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol 2002 20:189 94.
39. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001 61:237 42.
40. American Joint Committee on Cancer (AJCC). AJCC cancer staging manual, 5th edn. Philadelphia:Lippincott-Raven, 1997.
41. Hori T, Uchiyama T, Tsudo M et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987 70:1069 72.
42. Lelongt B, Bengatta S, Delauche M, Lund LR, Werb Z, Ronco PM. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Med 2001 193:793 802.
43. Liu Z, Shipley JM, Vu TH et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998 188:475 82.
44. Loughnan MS, Sanderson CJ, Nossal GJ. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5. Proc Natl Acad Sci USA 1988 85:3115 19.
45. Wagner DK, Wong HL, Gately MK, Nelson DL. Cellular source of soluble interleukin 2 receptors in serum of mice after recombinant interleukin 2 administration. Cytokine 1990 2:337 43.
46. Badoual C, Hans S, Rodriguez J et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006 12:465 72.
47. Belleguic C, Corbel M, Germain N et al. Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin Exp Allergy 2002 32:217 23.
48. Ikebe T, Shinohara M, Takeuchi H et al. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis 1999 17:315 23.
49. Giannelli G, Erriquez R, Fransvea E et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004 109:782 5.
50. Hornebeck W, Lambert E, Petitfrere E, Bernard P. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 2005 87:377 83.
51. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003 22:167 75.
52. Takahashi C, Sheng Z, Horan TP et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998 95:13221 6.
53. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000 1477:267 83.
54. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005 11:5390 5.
55. Bosse M, Chakir J, Rouabhia M, Boulet LP, Audette M, Laviolette M. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999 159:596 602.
56. Zucker S, Cao J. Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls. Clin Cancer Res 2005 11:5069 70.
57. Jung K, Meisser A, Bischof P. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer 2005 116:1000 1 author reply 2 3.
58. Alby C, Ben Abdesselam O, Foglietti MJ, Beaudeux JL. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin Chim Acta 2002 325:183 6.
59. Rouy D, Ernens I, Jeanty C, Wagner DR. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 2005 338:294 8.
60. Kleiner DE, Stetler-Stevenson WG Jr. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 1993 5:891 7.
61. Junghans RP, Waldmann TA. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 1996 183:1587 602.
62. Van den Steen PE, Husson SJ, Proost P, Van Damme J, Opdenakker G. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun 2003 310:889 96.
63. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 2003 270:3739 49.